Caleb Busch

Caleb Busch

Auto-generated profile, based on publicly available information

Caleb Busch

Department of Ophthalmology, Osaka University Graduate School of Medicine, Osaka, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Open access
PDF file
AWAndrew Winegarner
Andrew Winegarner
TWTaku Wakabayashi
Taku Wakabayashi
YFYoko Fukushima
Yoko Fukushima
TSTatsuhiko Sato
Tatsuhiko Sato
CHChikako Hara-Ueno
Chikako Hara-Ueno
KNKohji Nishida
Kohji Nishida
Purpose: To investigate the changes in the retinal microvasculature during the course of anti-VEGF therapy in eyes with macular edema due to retinal vein occlusion (RVO) and their association with visual outcomes. Methods: The vessel density (VD) and foveal avascular zone (FAZ) area in the superficial capillary plexus (SCP) and deep capillary plexus (DCP) were quantitatively measured by optical coherence tomography angiography (OCTA) in 48 consecutive eyes with RVO before and 1, 3, 6, 9, and 12 months after anti-VEGF therapy. Anti-VEGF therapy was performed either with ranibizumab or aflibercept following a pro re nata (PRN) regimen. The correlation between post-treatment best-corrected visual acuity (BCVA) and changes in the retinal microvasculature evaluated by OCTA were assessed. Results: The BCVA improved significantly at 12 months (P < 0.001). Better BCVA at 12 months was significantly associated with a better VD in the SCP and DCP both at baseline (R2 = 0.524, P < 0.001 and R2 = 0.457, P < 0.001, respectively) and at 12 months (R2 = 0.521, P < 0.001 and R2 = 0.662, P < 0.001, respectively). Overall, both VD and FAZ did not change significantly during the 12 months. However, the progression of nonperfusion was observed in the SCP in 6 (13%) eyes and in the DCP in 10 (21%) eyes. The number of macular edema recurrence was significantly associated with a decrease in the VD (P = 0.006 [SCP] and P < 0.001 [DCP]) and less visual gain (P = 0.02) after treatment. Conclusions: Anti-VEGF therapy maintains retinal perfusion in most patients with RVO. Preserving retinal perfusion is crucial for better visual outcomes.

24 July 2017 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
TSTatsuhiko Sato
Tatsuhiko Sato
MKMasanori Kanai
Masanori Kanai
CBCaleb Busch
Caleb Busch
TWTaku Wakabayashi
Taku Wakabayashi

1 October 2018 in Retina
Verified
Journal Article
Closed access
PDF file
AWAndrew Winegarner
Andrew Winegarner
TWTaku Wakabayashi
Taku Wakabayashi
CHChikako Hara-Ueno
Chikako Hara-Ueno
TSTatsuhiko Sato
Tatsuhiko Sato
CBCaleb Busch
Caleb Busch
KNKohji Nishida
Kohji Nishida
To investigate vascular perfusion and foveal avascular zone area in the superficial capillary plexus (SCP) and deep capillary plexus (DCP) after intravitreal aflibercept therapy in central retinal vein occlusion eyes and their association with best-corrected visual acuity. Thirty-five subjects with central retinal vein occlusion and macular edema were evaluated. After macular edema resolution following intravitreal aflibercept, subjects underwent optical coherence tomography angiography to measure SCP and DCP perfusion and the foveal avascular zone within a 3 × 3-mm area. Correlations between best-corrected visual acuity and optical coherence tomography angiography measurements were examined. After intravitreal aflibercept therapy, mean retinal vascular area was 3.41 ± 0.74 mm2 in the SCP and 3.25 ± 0.91 mm2 in the DCP. Foveal avascular zone area was 1.03 ± 1.04 mm2 in the SCP and 1.78 ± 1.73 mm2 in the DCP. Improved best-corrected visual acuity was significantly associated with better SCP and DCP perfusion (both P < 0.001) and with smaller SCP and DCP foveal avascular zone areas (both P < 0.001). Additionally, SCP and DCP perfusion were negatively correlated with macular edema before treatment (P < 0.05) and ischemia (determined via pretreatment fluorescein angiography, P < 0.05), and positively correlated with photoreceptor integrity (P < 0.001). Patients with better retinal perfusion and less retinal ischemia are associated with better visual outcomes after aflibercept in eyes with central retinal vein occlusion.

1 February 2019 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SHSusumu Hara
Susumu Hara
SKSatoshi Kawasaki
Satoshi Kawasaki
MYMasahito Yoshihara
Masahito Yoshihara
AWAndrew Winegarner
Andrew Winegarner
CBCaleb Busch
Caleb Busch
KNKohji Nishida
Kohji Nishida
The corneal endothelium, which originates from the neural crest via the periocular mesenchyme (PM), is crucial for maintaining corneal transparency. The development of corneal endothelial cells (CECs) from the neural crest is accompanied by the expression of several transcription factors, but the contribution of some of these transcriptional regulators to CEC development is incompletely understood. Here, we focused on activating enhancer-binding protein 2 (TFAP2, AP-2), a neural crest–expressed transcription factor. Using semiquantitative/quantitative RT-PCR and reporter gene and biochemical assays, we found that, within the AP-2 family, the TFAP2B gene is the only one expressed in human CECs in vivo and that its expression is strongly localized to the peripheral region of the corneal endothelium. Furthermore, the TFAP2B protein was expressed both in vivo and in cultured CECs. During mouse development, TFAP2B expression began in the PM at embryonic day 11.5 and then in CECs during adulthood. siRNA-mediated knockdown of TFAP2B in CECs decreased the expression of the corneal endothelium–specific proteins type VIII collagen alpha 2 (COL8A2) and zone pellucida glycoprotein 4 (ZP4) and suppressed cell proliferation. Of note, we also found that TFAP2B binds to the promoter of the COL8A2 and ZP4 genes. Furthermore, CECs that highly expressed ZP4 also highly expressed both TFAP2B and COL8A2 and showed high cell proliferation. These findings suggest that TFAP2B transcriptionally regulates CEC-specific genes and therefore may be an important transcriptional regulator of corneal endothelial development and homeostasis.

21 November 2018 in Asian Journal of Endoscopic Surgery
Verified
Journal Article
Closed access
PDF file
CBCaleb Busch
Caleb Busch
RNRyu Nakadate
Ryu Nakadate
MUMunenori Uemura
Munenori Uemura
SOSatoshi Obata
Satoshi Obata
TJTakahiro Jimbo
Takahiro Jimbo
MHMakoto Hashizume
Makoto Hashizume

14 July 2017 in Eye
Verified
Journal Article
Open access
PDF file
CBC Busch
C Busch
SKShizuka Koh
Shizuka Koh
YOY Oie
Y Oie
MIM Ichii
M Ichii
YKY Kanakura
Y Kanakura
KNK Nishida
K Nishida